<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01157104</url>
  </required_header>
  <id_info>
    <org_study_id>6844-002</org_study_id>
    <secondary_id>IDX-07A-002</secondary_id>
    <nct_id>NCT01157104</nct_id>
  </id_info>
  <brief_title>A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002)</brief_title>
  <official_title>A Phase I, Double-Blind, Multiple-Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between IDX320 and IDX184 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the potential for a pharmacokinetic (PK) drug-drug
      interaction between IDX320 and IDX184 and to assess the safety and tolerability when the two
      drugs are administered in combination in healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve at steady state (AUCss) of plasma IDX320</measure>
    <time_frame>Days 1-7 pre-dose; Day 7: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20 hrs postdose; Days 8-14 pre-dose; Day 14: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hrs postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCss of plasma IDX184</measure>
    <time_frame>Days 1-7 pre-dose; Day 7: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20 hrs postdose; Days 8-14 pre-dose; Day 14: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hrs postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCss of plasma 2'-methylguanosine (2'-MeG)</measure>
    <time_frame>Days 1-7 pre-dose; Day 7: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20 hrs postdose; Days 8-14 pre-dose; Day 14: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hrs postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) of plasma IDX320</measure>
    <time_frame>Days 1-7 pre-dose; Day 7: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20 hrs postdose; Days 8-14 pre-dose; Day 14: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hrs postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of plasma IDX184</measure>
    <time_frame>Days 1-7 pre-dose; Day 7: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20 hrs postdose; Days 8-14 pre-dose; Day 14: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hrs postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of plasma 2'-MeG</measure>
    <time_frame>Days 1-7 pre-dose; Day 7: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20 hrs postdose; Days 8-14 pre-dose; Day 14: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hrs postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough concentration (Ctrough) of plasma IDX320</measure>
    <time_frame>Days 1-7 pre-dose; Day 7: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20 hrs postdose; Days 8-14 pre-dose; Day 14: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hrs postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ctrough of plasma IDX184</measure>
    <time_frame>Days 1-7 pre-dose; Day 7: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20 hrs postdose; Days 8-14 pre-dose; Day 14: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hrs postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ctrough of plasma 2&quot;-MeG</measure>
    <time_frame>Days 1-7 pre-dose; Day 7: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20 hrs postdose; Days 8-14 pre-dose; Day 14: 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hrs postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with an adverse event (AE)</measure>
    <time_frame>Up to Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who discontinued treatment due to an AE</measure>
    <time_frame>Up to Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>IDX320 + PBO → IDX320 + IDX184</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg IDX320 and IDX184 matching placebo (PBO) once daily for 7 days; followed by 400 mg IDX320 and 100 mg IDX184 once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDX184 + PBO → IDX184 + IDX320</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg IDX184 and IDX320 matching PBO for 7 days; followed by 100 mg IDX184 and 400 mg IDX320 for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDX320 PBO + IDX184 PBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IDX320 matching PBO + IDX184 matching PBO for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDX320</intervention_name>
    <description>IDX320 400 mg in tablets (8x50 mg) administered orally once daily</description>
    <arm_group_label>IDX320 + PBO → IDX320 + IDX184</arm_group_label>
    <arm_group_label>IDX184 + PBO → IDX184 + IDX320</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDX184</intervention_name>
    <description>IDX184 100 mg in capsules (2x50 mg) administered orally once daily</description>
    <arm_group_label>IDX320 + PBO → IDX320 + IDX184</arm_group_label>
    <arm_group_label>IDX184 + PBO → IDX184 + IDX320</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDX184 placebo</intervention_name>
    <description>IDX184 matching placebo in capsules administered orally once daily</description>
    <arm_group_label>IDX320 + PBO → IDX320 + IDX184</arm_group_label>
    <arm_group_label>IDX320 PBO + IDX184 PBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDX320 placebo</intervention_name>
    <description>IDX320 matching placebo in tablets administered orally once daily</description>
    <arm_group_label>IDX184 + PBO → IDX184 + IDX320</arm_group_label>
    <arm_group_label>IDX320 PBO + IDX184 PBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To participate in the study, participants must meet the following requirements:

          1. Must be a healthy male or female between 19 and 65 years of age with body mass index
             (BMI) between 18 and 35 kg/m2.

          2. Must be a non-smoker.

          3. Must agree to use an acceptable double-barrier method of birth control.

          4. Must provide written informed consent after the study has been fully explained.

        Exclusion Criteria:

        Participants are not eligible if they meet any of the following:

          1. Pregnant or breastfeeding.

          2. History of clinically significant diseases, as determined by the investigator.

          3. Safety laboratory abnormalities at screening which are clinically significant.

          4. Positive screening test for hepatitis B virus, hepatitis C virus or human
             immunodeficiency virus (HIV).

          5. Use of chronic prescription medications within 3 months, acute prescription
             medications within 14 days, or systemic over-the-counter (OTC) medications within 7
             days of the starting the study.

          6. Current abuse of alcohol or illicit drugs, or history of alcohol or illicit drug abuse
             within the preceding two years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2010</study_first_submitted>
  <study_first_submitted_qc>July 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 5, 2010</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

